Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 162 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Pregnant Mom Had to Fight for a Diagnosis After Finding a... August 2, 2021 Good-bye, Old Friend January 8, 2021 FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... May 30, 2025 Pumpkin Season! October 27, 2020 Load more HOT NEWS Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective The stories behind Teenage and Young Adult Cancer Awareness Month Speaking a thousand words – how a cancer image collection is...
